Published in World J Surg Oncol on April 29, 2016
Cancer statistics, 2013. CA Cancer J Clin (2013) 84.72
Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol (2003) 8.31
Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol (2002) 6.51
Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol (2007) 4.06
ESPEN Guidelines on Enteral Nutrition: Surgery including organ transplantation. Clin Nutr (2006) 3.36
What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol (2006) 2.69
Surgical technique of en bloc pelvic resection for advanced ovarian cancer. J Gynecol Oncol (2015) 2.02
The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol (1992) 1.64
Angiogenesis in cancer. Vasc Health Risk Manag (2006) 1.49
Stapled versus handsewn methods for colorectal anastomosis surgery. Cochrane Database Syst Rev (2001) 1.36
Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecol Oncol (2001) 1.28
Anastomotic leakage after low anterior resection for rectal cancer: facts, obscurity, and fiction. Surg Today (2009) 1.21
Radical oophorectomy with primary stapled colorectal anastomosis for resection of locally advanced epithelial ovarian cancer. J Am Coll Surg (2003) 1.14
A critical appraisal of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancer. Gynecol Oncol (2014) 1.04
The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma - analysis of patient data in the prospective OVCAD study. Gynecol Oncol (2013) 1.03
Bowel anastomoses: The theory, the practice and the evidence base. World J Gastrointest Surg (2012) 0.99
Risk factors for anastomotic leak after recto-sigmoid resection for ovarian cancer. Gynecol Oncol (2006) 0.97
Colorectal cancer metastasis: in the surgeon's hands? Int Semin Surg Oncol (2005) 0.95
Morbidity of rectosigmoid resection and primary anastomosis in patients undergoing primary cytoreductive surgery for advanced epithelial ovarian cancer. Gynecol Oncol (2005) 0.95
Physiologic resection of the right colon. Surg Gynecol Obstet (1952) 0.94
Comparison of ECOG/WHO performance status and ASA score as a measure of functional status. J Pain Symptom Manage (2014) 0.94
A randomized controlled trial of the conventional technique versus the no-touch isolation technique for primary tumor resection in patients with colorectal cancer: Japan Clinical Oncology Group Study JCOG1006. Jpn J Clin Oncol (2013) 0.92
Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials. Eur J Cancer (2012) 0.92
The benefits of low anterior en bloc resection as part of cytoreductive surgery for advanced primary and recurrent epithelial ovarian cancer patients outweigh morbidity concerns. Gynecol Oncol (2006) 0.92
Reduced dissemination of circulating tumor cells with no-touch isolation surgical technique in patients with pancreatic cancer. JAMA Surg (2014) 0.86
Rectosigmoid resection at the time of primary cytoreduction for advanced ovarian cancer. A multi-center analysis of surgical and oncological outcomes. Gynecol Oncol (2012) 0.86
The Western Australian experience of the use of en bloc resection of ovarian cancer with concomitant rectosigmoid colectomy. Gynecol Oncol (2002) 0.84
En-bloc pelvic resection with concomitant rectosigmoid colectomy and immediate anastomosis as part of primary cytoreductive surgery for patients with advanced ovarian cancer. Eur J Gynaecol Oncol (2014) 0.78
Colon resection for ovarian cancer: intraoperative decisions. Gynecol Oncol (2008) 0.78
Advanced ovarian cancer: omental bursa, lesser omentum, celiac, portal and triad nodes spread as cause of inaccurate evaluation of residual tumor. Gynecol Oncol (2013) 0.78